Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis

What Was Tested

The paper reports a study of Teduglutide (GLP-2 analog), published as a randomized controlled trial.

Chronic hepatic complications are common in patients with short bowel syndrome-associated intestinal failure (SBS-IF).

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Teduglutide (GLP-2 analog) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Teduglutide (GLP-2 analog) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Teduglutide (GLP-2 analog), giving a reference point.

This was a post hoc analysis of pooled data from two separate randomized, double-blind, placebo-controlled, multinational phase 3 clinical studies.

Mixed-effects models assessed the baseline predictors of change in liver chemistries.

What Was Measured

Chronic hepatic complications are common in patients with short bowel syndrome-associated intestinal failure (SBS-IF).

The subject headings attached to it are Short Bowel Syndrome, Peptides, Liver, Gastrointestinal Agents, Aspartate Aminotransferases, Parenteral Nutrition and Alanine Transaminase.

Author keywords: glucagon‐like peptide‐2 and liver function tests.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teduglutide (GLP-2 analog).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition), a journal based in United States.

More context: the Teduglutide (GLP-2 analog) compound page, all human trials.